Stay updated on BrigHTN Study of CIN-107 in Treatment-Resistant Hypertension Clinical Trial
Sign up to get notified when there's something new on the BrigHTN Study of CIN-107 in Treatment-Resistant Hypertension Clinical Trial page.

Latest updates to the BrigHTN Study of CIN-107 in Treatment-Resistant Hypertension Clinical Trial page
- Check7 days agoChange DetectedAdded a government funding lapse notice indicating the site may not be up to date and that the NIH Clinical Center is open; updated the page revision from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check14 days agoChange DetectedAdded a Show glossary toggle and updated the QC status label to 'Last Update Submitted that Met QC Criteria'. Footer text updated to 'No FEAR Act Data' and the revision bumped from v3.3.4 to v3.4.0.SummaryDifference0.1%

- Check21 days agoChange DetectedRemoved several study document entries, including the Statistical Analysis Plan and the Study Protocol, from the Study Documents section. This reduces access to core methodological materials and related links.SummaryDifference16%

- Check28 days agoChange DetectedRevision: v3.3.4 was added, replacing the previous v3.3.3 listing. This appears to be a routine site version update and does not affect study data or page functionality.SummaryDifference0.0%

- Check49 days agoChange DetectedAdded a comprehensive Locations section listing study sites across multiple states and updated the revision from v3.3.2 to v3.3.3.SummaryDifference2%

- Check78 days agoChange DetectedRevision: v3.3.2 is added in the footer, replacing Revision: v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to BrigHTN Study of CIN-107 in Treatment-Resistant Hypertension Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BrigHTN Study of CIN-107 in Treatment-Resistant Hypertension Clinical Trial page.